Hong Kong Stock Movement: EDGE MEDICAL-B Soars 11.67% Due to the Exercise of Over-allotment Option! Increased Market Liquidity Draws Attention

Hong Kong Stock Movement EDGE MEDICAL-B rose 11.67%. Based on recent key news: On February 9, EDGE MEDICAL-B issued and allocated 4.1583 million H shares due to the full exercise of the over-allotment option. This move increased market liquidity, driving the stock price up by 11.67%. Source: Zhitong Finance. The recent volatility in the Hong Kong stock market requires attention to risks. Stocks Ranked High in Industry Transaction Volume MicroPort Robotics-B rose 4.74%. Based on recent key news: On February 9, the partnership between WeDoctor and Ant Group was emphasized. Although Ant has shown strong performance in the AI medical field, the threat to WeDoctor in the short term is limited. WeDoctor's IPO plans and the application of AI technology have attracted market attention, driving the stock price up. Source: Wall Street Insight. On February 9, Variable Robotics Technology added Alibaba Cloud Computing as a shareholder, increasing its registered capital. This change may enhance the company's competitiveness in the smart robotics field and boost market confidence. Source: Qichacha. No other significant news recently. The application of AI technology is widespread, and market attention is high. MicroPort Medical rose 1.81%. Based on recent key news: On February 10, the China International Medical Equipment and Devices Trading Platform was launched in Tianjin, promoting the global buying and selling of medical equipment and aiding the export of domestic equipment. MicroPort Medical benefited from this, leading to a rise in stock price. Source: Jinshi Data. On February 9, Ant Group upgraded its collaboration with WeDoctor to an AI intelligent entity. In the short term, Ant poses no threat to WeDoctor, which positively impacted MicroPort Medical's stock price. Source: Wall Street Insight. No other significant news recently. The globalization trend in the medical industry is evident. Angelalign fell 0.54%. Based on recent key news: On February 9, Goldman Sachs released a research report recommending a buy on Angelalign, believing that the medical device sector has bottomed out and will gradually recover. Goldman Sachs maintains a neutral view on the medical device sector but recommends buying Angelalign, considering its valuation reasonable and industry recovery promising. Source: Zhitong Finance. On February 9, Goldman Sachs pointed out that the strong trend in the mainland medical health sector last year will continue into this year, and investors need to consider the value of more R&D pipelines when assessing valuations. Goldman Sachs believes that stock trading is more based on the actual execution capabilities of companies rather than purely on licensing transaction expectations. Source: Zhitong Finance. On February 9, Goldman Sachs held a cautious attitude towards the medical services sector due to the ongoing impact of cost control measures and a weak consumption cycle. Goldman Sachs downgraded the rating of Haijia Medical to "neutral" but maintained a recommendation for Angelalign. Source: Zhitong Finance. The recovery of the medical device sector will take time, and valuations are reasonable. Stocks Ranked High in Industry Market Capitalization Guichuang Tongqiao rose 0.80%, with a market capitalization of HKD 8.493 billion, and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation